44 results on '"Krol, Augustinus D. G."'
Search Results
2. Relation between Coronary Artery Calcium Score and Cardiovascular Events in Hodgkin Lymphoma Survivors: A Cross-Sectional Matched Cohort Study
- Author
-
Polomski, Elissa A. S., primary, Heemelaar, Julius C., additional, de Graaf, Michiel A., additional, Krol, Augustinus D. G., additional, Louwerens, Marloes, additional, Stöger, J. Lauran, additional, van Dijkman, Paul R. M., additional, Schalij, Martin J., additional, Jukema, J. Wouter, additional, and Antoni, M. Louisa, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma
- Author
-
Geurts, Yvonne M., primary, Shakir, Rebecca, additional, Ntentas, Georgios, additional, Roberti, Sander, additional, Aznar, Marianne C., additional, John, Katinka M., additional, Ramroth, Johanna, additional, Janus, Cécile P. M., additional, Krol, Augustinus D. G., additional, Roesink, Judith M., additional, van der Maazen, Richard W. M., additional, Zijlstra, Josée M., additional, Darby, Sarah C., additional, Aleman, Berthe M. P., additional, van Leeuwen, Flora E., additional, Cutter, David J., additional, and Schaapveld, Michael, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC‐Dutch late effects cohort‐linked data
- Author
-
Juul, Sidsel Jacobsen, primary, Kicinski, Michal, additional, Schaapveld, Michael, additional, Rossetti, Sára, additional, Aleman, Berthe M. P., additional, Liu, Lifang, additional, van Leeuwen, Flora E., additional, Meijnders, Paul, additional, Krol, Augustinus D. G., additional, Janus, Cécile P. M., additional, Hutchings, Martin, additional, and Maraldo, Maja V., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma
- Author
-
Krul, Inge M., primary, Boekel, Naomi B., additional, Kramer, Iris, additional, Janus, Cécile P. M., additional, Krol, Augustinus D. G., additional, Nijziel, Marten R., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W. M., additional, Roesink, Judith M., additional, Jacobse, Judy N., additional, Schaapveld, Michael, additional, Schmidt, Marjanka K., additional, Opstal‐van Winden, Annemieke W. J., additional, Sonke, Gabe S., additional, Russell, Nicola S., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC‐Dutch late effects cohort‐linked data.
- Author
-
Juul, Sidsel Jacobsen, Kicinski, Michal, Schaapveld, Michael, Rossetti, Sára, Aleman, Berthe M. P., Liu, Lifang, van Leeuwen, Flora E., Meijnders, Paul, Krol, Augustinus D. G., Janus, Cécile P. M., Hutchings, Martin, and Maraldo, Maja V.
- Subjects
HODGKIN'S disease ,CLINICAL trials ,OVERALL survival ,UNITS of time - Abstract
Studies have shown higher survival rates for patients with Hodgkin lymphoma (HL) treated within clinical trials compared to patients treated outside clinical trials. However, endpoints are often limited to overall survival (OS). In this retrospective cohort study, we investigated the effect of trial participation on OS, the incidence of relapse, second cancer, and cardiovascular disease (CVD). The study population consisted of patients with HL, aged between 14 and 51 years at diagnosis, who started their treatment between 1962 and 2002 at three Dutch cancer centres. Patients were either included in the EORTC Lymphoma Group trials (H1–H9) or treated according to standard guidelines at the time. After adjusting for differences in baseline characteristics, trial participation was associated with longer OS (median OS: 29.4 years [95%CI: 27.0–31.6] for treatment inside trials versus 27.4 years [95%CI: 26.0–28.5] for treatment outside trials, p =.046), a lower incidence of relapse (HR = 0.79, 95%CI: 0.63–0.98, p =.036) and a higher incidence of CVD (HR = 1.49, 95%CI: 1.23–1.79, p <.001). The trial effect for CVD was present only for patients treated before 1983. No evidence of differences in the incidence of second cancer was found. Consequently, essential results from clinical trials should be implemented into standard practice without undue delay. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Impaired Global Longitudinal Strain Is Associated with Cardiovascular Events in Hodgkin Lymphoma Survivors
- Author
-
Polomski, Elissa A. S., primary, Heemelaar, Julius C., additional, Krol, Augustinus D. G., additional, Louwerens, Marloes, additional, Beeres, Saskia L. M. A., additional, Holman, Eduard R., additional, Jukema, J. Wouter, additional, Schalij, Martin J., additional, and Antoni, M. Louisa, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
- Author
-
Cutter, David J., Schaapveld, Michael, Darby, Sarah C., Hauptmann, Michael, van Nimwegen, Frederika A., Krol, Augustinus D. G., Janus, Cecile P. M., van Leeuwen, Flora E., and Aleman, Berthe M. P.
- Published
- 2015
- Full Text
- View/download PDF
9. Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
- Author
-
van Nimwegen, Frederika A., Schaapveld, Michael, Janus, Cécile P. M., Krol, Augustinus D. G., Petersen, Eefke J., Raemaekers, John M. M., Kok, Wouter E. M., Aleman, Berthe M. P., and van Leeuwen, Flora E.
- Published
- 2015
- Full Text
- View/download PDF
10. Persisting fatigue in Hodgkin lymphoma survivors: a systematic review
- Author
-
Daniëls, Laurien A., Oerlemans, Simone, Krol, Augustinus D. G., van de Poll-Franse, Lonneke V., and Creutzberg, Carien L.
- Published
- 2013
- Full Text
- View/download PDF
11. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma
- Author
-
Lansu, Jules, primary, Bovée, Judith V. M. G., additional, Braam, Pètra, additional, van Boven, Hester, additional, Flucke, Uta, additional, Bonenkamp, Johannes J., additional, Miah, Aisha B., additional, Zaidi, Shane H., additional, Thway, Khin, additional, Bruland, Øyvind S., additional, Baldini, Elizabeth H., additional, Jebsen, Nina L., additional, Scholten, Astrid N., additional, van den Ende, Piet L. A., additional, Krol, Augustinus D. G., additional, Ubbels, Jan F., additional, van der Hage, Jos A., additional, van Werkhoven, Erik, additional, Klomp, Houke M., additional, van der Graaf, Winette T. A., additional, van Coevorden, Frits, additional, Schrage, Yvonne, additional, van Houdt, Winan J., additional, and Haas, Rick L., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
- Author
-
de Vries, Simone, primary, Schaapveld, Michael, additional, Janus, Cécile P M, additional, Daniëls, Laurien A, additional, Petersen, Eefke J, additional, van der Maazen, Richard W M, additional, Zijlstra, Josée M, additional, Beijert, Max, additional, Nijziel, Marten R, additional, Verschueren, Karijn M S, additional, Kremer, Leontien C M, additional, van Eggermond, Anna M, additional, Lugtenburg, Pieternella J, additional, Krol, Augustinus D G, additional, Roesink, Judith M, additional, Plattel, Wouter J, additional, van Spronsen, Dick Johan, additional, van Imhoff, Gustaaf W, additional, de Boer, Jan Paul, additional, Aleman, Berthe M P, additional, and van Leeuwen, Flora E, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet
- Author
-
Haas, Rick L., primary, Walraven, Iris, additional, Lecointe‐Artzner, Estelle, additional, Houdt, Winan J., additional, Strauss, Dirk, additional, Schrage, Yvonne, additional, Hayes, Andrew J., additional, Raut, Chandrajit P., additional, Fairweather, Mark, additional, Baldini, Elizabeth H., additional, Gronchi, Alessandro, additional, De Rosa, Laura, additional, Griffin, Anthony M., additional, Ferguson, Peter C., additional, Wunder, Jay, additional, Sande, Michiel A. J., additional, Krol, Augustinus D. G., additional, Skoczylas, Jacus, additional, Sangalli, Claudia, additional, and Stacchiotti, Silvia, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma
- Author
-
De Bruin, Marie L., Dorresteijn, Lucille D. A., vanʼt Veer, Mars B., Krol, Augustinus D. G., van der Pal, Helena J., Kappelle, Arnoud C., Boogerd, Willem, Aleman, Berthe M. P., and van Leeuwen, Flora E.
- Published
- 2009
15. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
- Author
-
Opstal-van Winden, Annemieke W J, de Haan, Hugoline G, Hauptmann, Michael, Schmidt, Marjanka K, Broeks, Annegien, Russell, Nicola S, Janus, Cécile P M, Krol, Augustinus D G, van der Baan, Frederieke H, De Bruin, Marie L, van Eggermond, Anna M, Dennis, Joe, Anton Culver, Hoda, Haiman, Christopher A, Sawyer, Elinor J, Cox, Angela, Devilee, Peter, Hooning, Maartje J, Peto, Julian, Couch, Fergus J, Pharoah, Paul, Orr, Nick, Easton, Douglas F, Aleman, Berthe M P, Strong, Louise C, Bhatia, Smita, Cooke, Rosie, Robison, Leslie L, Swerdlow, Anthony J, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, Medical Oncology, de Haan, Hugoline G [0000-0003-1126-4776], Schmidt, Marjanka K [0000-0002-2228-429X], De Bruin, Marie L [0000-0001-9197-7068], Dennis, Joe [0000-0003-4591-1214], Pharoah, Paul [0000-0001-8494-732X], Apollo - University of Cambridge Repository, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology
- Subjects
0301 basic medicine ,Oncology ,Neoplasms, Radiation-Induced ,medicine.medical_treatment ,Biochemistry ,single nucleotide polymorphisms ,0302 clinical medicine ,Cancer Survivors ,Genotype ,Taverne ,Odds Ratio ,Young adult ,skin and connective tissue diseases ,Aged, 80 and over ,education.field_of_study ,Neoplasms, Second Primary ,Radiotherapy Dosage ,Hematology ,Middle Aged ,Hodgkin Disease ,030220 oncology & carcinogenesis ,Regression Analysis ,Female ,Adult ,Quality Control ,Risk ,medicine.medical_specialty ,Immunology ,Population ,Breast Neoplasms ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,Young Adult ,Breast cancer ,breast cancer ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Genetic predisposition ,Humans ,Genetic Predisposition to Disease ,education ,radiotherapy ,Aged ,business.industry ,Case-control study ,Cell Biology ,Odds ratio ,medicine.disease ,Radiation therapy ,030104 developmental biology ,Case-Control Studies ,polygenic risk score ,business ,Hodgkin lymphoma ,genetic susceptibility - Abstract
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate
- Published
- 2019
16. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
- Author
-
Vries, Simone de, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, Maazen, Richard W M van der, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, Eggermond, Anna M van, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, Spronsen, Dick Johan van, Imhoff, Gustaaf W van, Boer, Jan Paul de, and Aleman, Berthe M P
- Subjects
HODGKIN'S disease ,CARDIOVASCULAR disease related mortality ,DEATH rate ,MORTALITY ,SPLEEN ,CAUSES of death ,RESEARCH ,RESEARCH methodology ,CANCER relapse ,EVALUATION research ,COMPARATIVE studies ,SECONDARY primary cancer ,LONGITUDINAL method - Abstract
Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients.Methods: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated.Results: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02).Conclusions: Compared with the general population, HL survivors have a substantially reduced life expectancy. Optimal selection of patients for primary CT is crucial, weighing risks of HL relapse and long-term toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood
- Author
-
van Leeuwen, Flora E., Klokman, Willem J., Veer, Mars B. van’t, Hagenbeek, Anton, Krol, Augustinus D. G., Vetter, Ursula A. O., Schaapveld, Michael, van Heerde, Peter, Burgers, J. Marion V., Somers, Reinier, and Aleman, Berthe M. P.
- Published
- 2000
18. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure
- Author
-
Krul, Inge M, Opstal-van Winden, Annemieke W J, Aleman, Berthe M P, Janus, Cécile P M, van Eggermond, Anna M, De Bruin, Marie L, Hauptmann, Michael, Krol, Augustinus D G, Schaapveld, Michael, Broeks, Annegien, Kooijman, Karen R, Fase, Sandra, Lybeert, Marnix L, Zijlstra, Josée M, van der Maazen, Richard W M, Kesminiene, Ausrele, Diallo, Ibrahima, de Vathaire, Florent, Russell, Nicola S, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, CCA - Cancer Treatment and quality of life, Hematology, APH - Quality of Care, and Epidemiology and Data Science
- Subjects
Oncology ,Cancer Research ,Neoplasms, Radiation-Induced ,Time Factors ,medicine.medical_treatment ,Menopause, Premature ,Procarbazine ,Noninfiltrating ,0302 clinical medicine ,Risk Factors ,Neoplasms ,Taverne ,030212 general & internal medicine ,Breast ,Survivors ,Young adult ,Gonadal Steroid Hormones ,Netherlands ,Radiation ,Radiotherapy Dosage ,Middle Aged ,Alkylating ,Hodgkin Disease ,Menopause ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,Adult ,medicine.medical_specialty ,Hormone Replacement Therapy ,Intraductal ,Antineoplastic Agents ,Breast Neoplasms ,Dose-Response Relationship ,03 medical and health sciences ,Young Adult ,Breast cancer ,SDG 3 - Good Health and Well-being ,Internal medicine ,Journal Article ,medicine ,Confidence Intervals ,Humans ,Radiology, Nuclear Medicine and imaging ,Premature ,Antineoplastic Agents, Alkylating ,Gynecology ,business.industry ,Carcinoma ,Ovary ,Case-control study ,Dose-Response Relationship, Radiation ,Odds ratio ,medicine.disease ,Radiation therapy ,Carcinoma, Intraductal, Noninfiltrating ,Radiation-Induced ,Case-Control Studies ,business ,Hormone - Abstract
Item does not contain fulltext BACKGROUND: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk. METHODS: We conducted a nested case-control study among female 5-year HL survivors treated before age 41. Hormone exposure and HL treatment data were collected through medical records and questionnaires for 174 BC case patients and 466 control patients. Radiation dose to breast tumor location was estimated based on RT charts, simulation films, and mammography reports. RESULTS: We observed a linear radiation dose-response curve with an adjusted excess odds ratio (EOR) of 6.1%/Gy (95% confidence interval [CI]: 2.1%-15.4%). Women with menopause /=50 years. BC risk increased by 6.4% per additional year of post-RT intact ovarian function (P/=2 years did not increase BC risk (OR, 0.86; 95% CI, 0.32-2.32), whereas this risk was nonsignificantly increased among women without early menopause (OR, 3.69; 95% CI, 0.97-14.0; P for interaction: .06). Stratification by duration of post-RT intact ovarian function or HRT use did not statistically significantly modify the radiation dose-response curve. CONCLUSIONS: BC risk in female HL survivors increases linearly with radiation dose. HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship.
- Published
- 2017
19. Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
- Author
-
Rigter, Lisanne S., primary, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Krol, Augustinus D. G., additional, van der Maazen, Richard W. M., additional, Roesink, Judith, additional, Zijlstra, Josee M., additional, van Imhoff, Gustaaf W., additional, Poortmans, Philip M. P., additional, Beijert, Max, additional, Lugtenburg, Pieternella J., additional, Visser, Otto, additional, Snaebjornsson, Petur, additional, van Eggermond, Anna M., additional, Aleman, Berthe M. P., additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional
- Published
- 2018
- Full Text
- View/download PDF
20. Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.
- Author
-
Rigter, Lisanne S., Schaapveld, Michael, Janus, Cecile P. M., Krol, Augustinus D. G., Maazen, Richard W. M., Roesink, Judith, Zijlstra, Josee M., Imhoff, Gustaaf W., Poortmans, Philip M. P., Beijert, Max, Lugtenburg, Pieternella J., Visser, Otto, Snaebjornsson, Petur, Eggermond, Anna M., Aleman, Berthe M. P., Leeuwen, Flora E., and Leerdam, Monique E.
- Subjects
CANCER patients ,TUMOR classification ,HODGKIN'S disease ,GASTROINTESTINAL cancer ,INTESTINAL tumors ,RADIOTHERAPY - Abstract
Background: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. Methods: Overall and cause‐specific survival of GI cancer patients in a HL survivor cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. Results: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile range 45‐60). No differences in tumor stage or frequency of surgery were found. GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively). Conclusions: Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival. Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study evaluated whether survival of a cohort of 104 patients who survived HL and developed GI cancer differs from survival of a large population‐based cohort of first primary GI cancer patients. Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients and this could not be explained by differences in tumor stage, grade of differentiation, or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma
- Author
-
van Eggermond, Anna M., primary, Schaapveld, Michael, additional, Lugtenburg, Pieternella J., additional, Krol, Augustinus D. G., additional, de Boer, Jan Paul, additional, Zijlstra, Josée M., additional, Raemaekers, John M. M., additional, Kremer, Leontien C. M., additional, Roesink, Judith M., additional, Louwman, Marieke W. J., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional
- Published
- 2014
- Full Text
- View/download PDF
22. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.
- Author
-
van Nimwegen, Frederika A., Schaapveld, Michael, Cutter, David J., Janus, Cècile P. M., Krol, Augustinus D. G., Hauptmann, Michael, Kooijman, Karen, Roesink, Judith, van der Maazen, Richard, Darby, Sarah C., Aleman, Berthe M. P., and van Leeuwen, Flora E.
- Published
- 2016
- Full Text
- View/download PDF
23. Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease
- Author
-
Kuper-Hommel, Marion J. J., primary, Janssen-Heijnen, Maryska L. G., additional, Vreugdenhil, Gerard, additional, Krol, Augustinus D. G., additional, Kluin-Nelemans, Hanneke C., additional, Coebergh, Jan-Willem W., additional, and van Krieken, J. Han J. M., additional
- Published
- 2011
- Full Text
- View/download PDF
24. Long-term Results
- Author
-
Moojen, Wouter A., primary, Vleggeert-Lankamp, Carmen L. A., additional, Krol, Augustinus D. G., additional, and Dijkstra, Sander P. D., additional
- Published
- 2011
- Full Text
- View/download PDF
25. Risk of Diabetes Mellitus in Long-Term Survivors of Hodgkin Lymphoma.
- Author
-
van Nimwegen, Frederika A., Schaapveld, Michael, Janus, Cecile P. M., Krol, Augustinus D. G., Raemaekers, John M. M., Kremer, Leontien C. M., Stovall, Marilyn, Aleman, Berthe M. P., and van Leeuwen, Flora E.
- Published
- 2014
- Full Text
- View/download PDF
26. Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease.
- Author
-
Kuper-Hommel, Marion J. J., Janssen-Heijnen, Maryska L. G., Vreugdenhil, Gerard, Krol, Augustinus D. G., Kluin-Nelemans, Hanneke C., Coebergh, Jan-Willem W., and van Krieken, J. Han J. M.
- Subjects
B cell lymphoma ,LYMPHOMAS ,LYMPHOPROLIFERATIVE disorders ,PLASMA cell leukemia ,PLASMACYTOMA - Abstract
Most testicular lymphomas are of diffuse large B-cell (DLBCL) type with an outcome inferior to nodal DLBCL. Within an apparently homogeneous group of testicular DLBCLs, small cell components, plasmacytoid differentiation and lymphoepithelial lesions (LELs), features of extranodal marginal zone lymphoma (eMZL), can be identified. The aim of this study was to define the histological features of testicular DLBCL and correlate this with their clinical behavior and outcome. Thirty-six patients with testicular DLBCL (Ann Arbor stage I/II) were identified through the databases of two Dutch regional cancer registries, diagnosed between 1981 and 1999. Follow-up for patients alive was more than 10 years. Medical records and pathology specimens were reviewed. eMZL features were found in 53% of the cases of localized stage testicular DLBCL. Compared to patients with 'pure' DLBCL, patients with DLBCL with eMZL features presented more often with stage I disease, normal lactate dehydrogenase, smaller tumors and absence of B-symptoms, and they responded more favorably to initial treatment. Their median survival was 48 months versus 12 months for 'pure' DLBCL ( p == 0.87). Features of eMZL were commonly identified in testicular DLBCL and they correlated with a more favorable clinical presentation and better response to initial therapy. However, these differences did not reach statistical significance due to small numbers. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
27. Re: Late Effects From Radiation Therapy: The Hits Just Keep on Coming.
- Author
-
ALEMAN, BERTHE M. P., De BRUIN, MARIE L., DORRESTEIJN, LUCILLE D. A., KROL, AUGUSTINUS D. G., VEER, MARS B. van't, BOOGERD, WILLEM, and VAN LEEUWEN, FLORA E.
- Subjects
CEREBROVASCULAR disease ,TRANSIENT ischemic attack ,HODGKIN'S disease ,RADIOTHERAPY - Abstract
The article presents the response of the authors to a reaction by D. L. Longo to their study on the increased risk of stroke and transient ischemic attack following Hodgkin lymphoma. Longo made a criticism on the use of radiotherapy in the treatment of Hodgkin lymphoma. Longo further mentioned that the effectivity of chemotherapy may be compared to combined modality treatment. The authors argue that Longo overestimated the effectivity of chemotherapy alone in the treatment and underestimated its toxicity.
- Published
- 2010
- Full Text
- View/download PDF
28. Risk of valvular heart disease after treatment for Hodgkin lymphoma.
- Author
-
Cutter, David J, Schaapveld, Michael, Darby, Sarah C, Hauptmann, Michael, van Nimwegen, Frederika A, Krol, Augustinus D G, Janus, Cecile P M, van Leeuwen, Flora E, and Aleman, Berthe M P
- Abstract
Background: Hodgkin lymphoma (HL) survivors are at increased risk of developing valvular heart disease (VHD). We evaluated the determinants of the risk and the radiation dose-response.Methods: A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical tests were two-sided.Results: Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with radiation dose. For doses to the affected valve(s) of less than or equal to 30, 31-35, 36-40, and more than 40 Gy, VHD rates increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively (P trend < .001). Approximate 30-year cumulative risks were 3.0%, 6.4%, 9.3%, and 12.4% for the same dose categories. VHD rate increased with splenectomy by a factor of 2.3 (P = .02).Conclusions: Radiation dose to the heart valves can increase the risk of clinically significant VHD, especially at doses above 30 Gy. However, for patients with mediastinal involvement treated today with 20 or 30 Gy, the 30-year risk will be increased by only about 1.4%. These findings may be useful for patients and doctors both before treatment and during follow-up. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
29. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
- Author
-
Schaapveld, Michael, Aleman, Berthe M. P., van Eggermond, Anna M., Janus, Cecile P. M., Krol, Augustinus D. G., van der Maazen, Richard W. M., Roesink, Judith, Raemaekers, John M. M., de Boer, Jan Paul, Zijlstra, Joste M., van Imhoff, Gustaaf W., Petersen, Eefke J., Poortmans, Philip M. P., Beijert, Max, Lybeert, Marnix L., Mulder, Ina, Visser, Otto, Louwman, Marieke W. J., Krul, Inge M., and Lugtenburg, Pieternella J.
- Abstract
Background: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown.Methods: We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma. Patients had received treatment between 1965 and 2000, when they were 15 to 50 years of age. We compared the risk of a second cancer among these patients with the risk that was expected on the basis of cancer incidence in the general population. Treatment-specific risks were compared within the cohort.Results: With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988, or 1989-2000) (P=0.71 for heterogeneity). Although the risk of breast cancer was lower among patients who were treated with supradiaphragmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was not lower among patients treated in the 1989-2000 study period than among those treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more per square meter of body-surface area (which has been associated with premature menopause) was associated with a significantly lower risk of breast cancer (hazard ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.84) but a higher risk of gastrointestinal cancer (hazard ratio, 2.70; 95% CI, 1.69 to 4.30).Conclusions: The risk of second solid cancers did not appear to be lower among patients treated in the most recent calendar period studied (1989-2000) than among those treated in earlier periods. The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's lymphoma. (Funded by the Dutch Cancer Society.). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
30. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
- Author
-
de Vries S, Haaksma ML, Jóźwiak K, Schaapveld M, Hodgson DC, Lugtenburg PJ, Krol ADG, Petersen EJ, van Spronsen DJ, Ahmed S, Hauptmann M, Aleman BMP, and van Leeuwen FE
- Subjects
- Adult, Adolescent, Humans, Child, Young Adult, Middle Aged, Canada, Risk Factors, Hodgkin Disease therapy, Heart Failure chemically induced, Heart Failure epidemiology, Cardiovascular Diseases epidemiology, Coronary Disease complications
- Abstract
Purpose: Previous efforts to predict absolute risk of treatment-related cardiovascular diseases (CVDs) have mostly focused on childhood cancer survivors. We aimed to develop prediction models for risk of coronary heart disease (CHD) and heart failure (HF) for survivors of adolescent/adult Hodgkin lymphoma (HL)., Methods: For model development, we used a multicenter cohort including 1,433 5-year HL survivors treated between 1965 and 2000 and age 18-50 years at HL diagnosis, with complete data on administered chemotherapy regimens, radiotherapy volumes and doses, and cardiovascular follow-up. Using cause-specific hazard models, covariate-adjusted cumulative incidences for CHD and HF were estimated in the presence of competing risks of death because of other causes than CHD and HF. Age at HL diagnosis, sex, smoking status, radiotherapy, and anthracycline treatment were included as predictors. External validation for the CHD model was performed using a Canadian cohort of 708 HL survivors treated between 1988 and 2004 and age 18-50 years at HL diagnosis., Results: After a median follow-up of 24 years, 341 survivors had developed CHD and 102 had HF. We were able to predict CHD and HF risk at 20 and 30 years after treatment with moderate to good overall calibration and moderate discrimination (areas under the curve: 0.68-0.74), which was confirmed by external validation for the CHD model (areas under the curve: 0.73-0.74). On the basis of our model including prescribed mediastinal radiation dose, 30-year risks ranged from 4% to 78% for CHD and 3% to 46% for HF, depending on risk factors., Conclusion: We developed and validated prediction models for CHD and HF with good overall calibration and moderate discrimination. These models can be used to identify HL survivors who might benefit from targeted screening for CVD and early treatment for CVD risk factors.
- Published
- 2023
- Full Text
- View/download PDF
31. Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation.
- Author
-
Kroesen M, Miladinovic V, Hutschemaekers SAJ, Jacobs J, van der Vos C, Wolf AL, Hoogeman MS, van Vulpen M, Bloem JL, P D S Dijkstra S, Peul WC, Penninkhof JJ, and Krol ADG
- Subjects
- Feasibility Studies, Humans, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Retrospective Studies, Sacrum, Bone Neoplasms radiotherapy, Chondrosarcoma radiotherapy, Chordoma radiotherapy, Proton Therapy adverse effects, Radiotherapy, Intensity-Modulated
- Abstract
Background: Due to its specific physical characteristics, proton irradiation is especially suited for irradiation of chordomas and chondrosarcoma in the axial skeleton. Robust plan optimization renders the proton beam therapy more predictable upon individual setup errors. Reported experience with the planning and delivery of robustly optimized plans in chordoma and chondrosarcoma of the mobile spine and sacrum, is limited. In this study, we report on the clinical use of robustly optimized, intensity modulated proton beam therapy in these patients., Methods: We retrospectively reviewed patient, treatment and acute toxicity data of all patients with chordoma and chondrosarcoma of the mobile spine and sacrum, treated between 1 April 2019 and 1 April 2020 at our institute. Anatomy changes during treatment were evaluated by weekly cone-beam CTs (CBCT), supplemented by scheduled control-CTs or ad-hoc control-CTs. Acute toxicity was scored weekly during treatment and at 3 months after therapy according to CTCAE 4.0., Results: 17 chordoma and 3 chondrosarcoma patients were included. Coverage of the high dose clinical target volume was 99.8% (range 56.1-100%) in the nominal and 80.9% (range 14.3-99.6%) in the voxel-wise minimum dose distribution. Treatment plan adaptation was needed in 5 out of 22 (22.7%) plans. Reasons for plan adaptation were either reduced tumor coverage or increased dose to the OAR., Conclusions: Robustly optimized intensity modulated proton beam therapy for chordoma and chondrosarcoma of the mobile spine is feasible. Plan adaptations due to anatomical changes were required in approximately 23 percent of treatment courses., Competing Interests: Conflict of interest statement None of the authors on this manuscript have any conflict of interest to declare., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Elevated resting heart rate is a marker of subclinical left ventricular dysfunction in hodgkin lymphoma survivors.
- Author
-
Heemelaar JC, Krol ADG, Louwerens M, L M A Beeres S, Holman ER, Schalij MJ, and Louisa Antoni M
- Abstract
Background: Thoracic irradiation is one of the cornerstones of Hodgkin lymphoma (HL) treatment, which contributes to high rates of long-term survivorship, but begets a life-long increased risk of heart disease including heart failure. At the cardio-oncology (CO) clinic, persistent sinus tachycardia or elevated resting heart rate (RHR) is frequently observed in these patients. The aim of this study was to evaluate the relation between RHR and left ventricular (LV) dysfunction., Methods: In 75 HL survivors visiting our CO-clinic echocardiographic evaluation of LV systolic and diastolic function including global longitudinal strain (GLS) was performed to assess subclinical LV dysfunction., Results: Median age of HL diagnosis was 24 [25th-75th percentile: [19], [29]] years with a 17 [12], [25] year interval to CO-clinic visit and 31 patients (41%) were male. Average RHR was 78 ± 14 bpm and 40% of patients (N = 30) had an elevated RHR defined as ≥ 80 bpm. While there was no difference in LV ejection fraction (55.6 ± 4.3 vs . 54.8 ± 6.6; p = 0.543), patients with elevated RHR had abnormal GLS (-15.9% vs . -18.3%, p = 0.045) and higher prevalence of diastolic dysfunction (73.3% vs . 46.7%; p = 0.022). GLS, E/e' ratio and presence of diastolic dysfunction were independently associated with RHR when correcting for age, sex and mantle field irradiation. A significant improvement was observed of the RHR-association model with solely extracardiac confounders when LV-function parameters were added to the model (F-statistic = 6.36, p = 0.003)., Conclusions: This study indicates RHR as a possible marker for subclinical LV-dysfunction in HL survivors., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
33. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
- Author
-
de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, and van Leeuwen FE
- Subjects
- Cause of Death, Cohort Studies, Humans, Middle Aged, Neoplasm Recurrence, Local, Risk Factors, Survivors, Hodgkin Disease drug therapy, Neoplasms, Second Primary epidemiology
- Abstract
Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients., Methods: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated., Results: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02)., Conclusions: Compared with the general population, HL survivors have a substantially reduced life expectancy. Optimal selection of patients for primary CT is crucial, weighing risks of HL relapse and long-term toxicity., (© The Author(s) 2020. Published by Oxford University Press.)
- Published
- 2021
- Full Text
- View/download PDF
34. Therapy-Related Imaging Findings in Patients with Sarcoma.
- Author
-
Bloem JL, Vriens D, Krol ADG, Özdemir M, Sande MAJV, Gelderblom H, Bovee JVMG, Hage JAV, and Noebauer-Huhmann IM
- Subjects
- Humans, Neoplasm Recurrence, Local diagnostic imaging, Quality of Life, Sarcoma diagnostic imaging, Sarcoma therapy
- Abstract
Knowledge of imaging findings related to therapy administered to patients with sarcoma is pivotal in selecting appropriate care for these patients. Imaging studies are performed as surveillance in asymptomatic patients or because symptoms, including anxiety, develop. In addition to detection of recurrent disease and assessment of response to therapy, diagnosis of conditions related to therapy that may or may not need treatment has a marked positive impact on quality of life. The purpose of this review is to assist radiologists, nuclear physicians, and others clinicians involved in the diagnosis and treatment of these patients in recognizing imaging findings related to therapy and not to activity of the previously treated sarcoma. Imaging findings are time dependent and often specific in relation to therapy given., Competing Interests: Disclosure The authors report no conflicts of interest in this work., (Thieme. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.
- Author
-
Opstal-van Winden AWJ, de Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CPM, Krol ADG, van der Baan FH, De Bruin ML, van Eggermond AM, Dennis J, Anton-Culver H, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr N, Easton DF, Aleman BMP, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, and van Leeuwen FE
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms etiology, Cancer Survivors, Case-Control Studies, Female, Genotype, Hodgkin Disease complications, Humans, Middle Aged, Neoplasms, Second Primary genetics, Odds Ratio, Polymorphism, Single Nucleotide, Quality Control, Radiotherapy Dosage, Regression Analysis, Risk, Young Adult, Breast Neoplasms genetics, Genetic Predisposition to Disease, Hodgkin Disease genetics, Hodgkin Disease radiotherapy, Neoplasms, Radiation-Induced genetics
- Abstract
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate, <20%), of which 1 SNP in the PVT1 oncogene attained the Bonferroni threshold for statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-interaction-PRS) and a previously published breast cancer PRS (BC-PRS) derived in the general population were evaluated in a case-control analysis comprising the 327 chest-irradiated HL patients with breast cancer and 491 chest-irradiated HL patients without breast cancer. Patients in the highest tertile of the RT-interaction-PRS had a 1.6-fold higher breast cancer risk than those in the lowest tertile. Remarkably, we observed a fourfold increased RT-induced breast cancer risk in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, breast cancer risk increased 1.4-fold per standard deviation of the BC-PRS, similar to the effect size found in the general population. This study demonstrates that genetic factors influence breast cancer risk after chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed women, these results can have important implications for the management of current HL survivors and future patients., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
36. The impact of treatment accuracy on proton therapy patient selection for oropharyngeal cancer patients.
- Author
-
Arts T, Breedveld S, de Jong MA, Astreinidou E, Tans L, Keskin-Cambay F, Krol ADG, van de Water S, Bijman RG, and Hoogeman MS
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Proton Therapy adverse effects, Radiotherapy Planning, Computer-Assisted methods, Xerostomia etiology, Oropharyngeal Neoplasms radiotherapy, Patient Selection, Proton Therapy methods, Radiotherapy, Intensity-Modulated methods
- Abstract
Background and Purpose: The impact of treatment accuracy on NTCP-based patient selection for proton therapy is currently unknown. This study investigates this impact for oropharyngeal cancer patients., Materials and Methods: Data of 78 patients was used to automatically generate treatment plans for a simultaneously integrated boost prescribing 70 Gy
RBE /54.25 GyRBE in 35 fractions. IMRT treatment plans were generated with three different margins; intensity modulated proton therapy (IMPT) plans for five different setup and range robustness settings. Four NTCP models were evaluated. Patients were selected for proton therapy if NTCP reduction was ≥10% or ≥5% for grade II or III complications, respectively., Results: The degree of robustness had little impact on patient selection for tube feeding dependence, while the margin had. For other complications the impact of the robustness setting was noticeably higher. For high-precision IMRT (3 mm margin) and high-precision IMPT (3 mm setup/3% range error), most patients were selected for proton therapy based on problems swallowing solid food (51.3%) followed by tube feeding dependence (37.2%), decreased parotid flow (29.5%), and patient-rated xerostomia (7.7%)., Conclusions: Treatment accuracy has a significant impact on the number of patients selected for proton therapy. Therefore, it cannot be ignored in estimating the number of patients for proton therapy., (Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
37. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.
- Author
-
Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, and van Leeuwen FE
- Subjects
- Adult, Antineoplastic Agents adverse effects, Antineoplastic Agents, Alkylating adverse effects, Antineoplastic Agents, Alkylating therapeutic use, Breast drug effects, Carcinoma, Intraductal, Noninfiltrating etiology, Case-Control Studies, Confidence Intervals, Dose-Response Relationship, Radiation, Female, Hodgkin Disease drug therapy, Hormone Replacement Therapy adverse effects, Humans, Menopause, Premature, Middle Aged, Netherlands, Ovary physiology, Procarbazine adverse effects, Radiotherapy Dosage, Risk Factors, Survivors, Time Factors, Young Adult, Breast radiation effects, Breast Neoplasms etiology, Gonadal Steroid Hormones pharmacology, Gonadal Steroid Hormones physiology, Hodgkin Disease radiotherapy, Neoplasms, Radiation-Induced etiology
- Abstract
Background: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk., Methods: We conducted a nested case-control study among female 5-year HL survivors treated before age 41. Hormone exposure and HL treatment data were collected through medical records and questionnaires for 174 BC case patients and 466 control patients. Radiation dose to breast tumor location was estimated based on RT charts, simulation films, and mammography reports., Results: We observed a linear radiation dose-response curve with an adjusted excess odds ratio (EOR) of 6.1%/Gy (95% confidence interval [CI]: 2.1%-15.4%). Women with menopause <30 years (caused by high-dose procarbazine or pelvic RT) had a lower BC risk (OR, 0.13; 95% CI, 0.03-0.51) than did women with menopause ≥50 years. BC risk increased by 6.4% per additional year of post-RT intact ovarian function (P<.001). Among women with early menopause (<45 years), hormone replacement therapy (HRT) use for ≥2 years did not increase BC risk (OR, 0.86; 95% CI, 0.32-2.32), whereas this risk was nonsignificantly increased among women without early menopause (OR, 3.69; 95% CI, 0.97-14.0; P for interaction: .06). Stratification by duration of post-RT intact ovarian function or HRT use did not statistically significantly modify the radiation dose-response curve., Conclusions: BC risk in female HL survivors increases linearly with radiation dose. HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Sexual Concerns after (Pelvic) Radiotherapy: Is There Any Role for the Radiation Oncologist?
- Author
-
Krouwel EM, Nicolai MP, van der Wielen GJ, Putter H, Krol AD, Pelger RC, Incrocci L, and Elzevier HW
- Subjects
- Aged, Attitude of Health Personnel, Cross-Sectional Studies, Female, Health Services Needs and Demand, Humans, Male, Middle Aged, Netherlands, Patient Care Team, Practice Patterns, Physicians', Quality of Life psychology, Radiation Injuries etiology, Radiation Injuries psychology, Surveys and Questionnaires, Coitus psychology, Pelvic Neoplasms radiotherapy, Radiation Injuries prevention & control, Radiation Oncology education, Sex Counseling methods
- Abstract
Introduction: Sexual function is an important aspect of quality of life, and may be impaired after (pelvic) radiation., Aim: The aim of this study was to identify practice, responsibility attitudes, knowledge, and barriers of Dutch radiation oncologists regarding sexual counseling., Methods: A cross-sectional survey was performed using a 28-item questionnaire sent to all members of the Dutch Society for Radiotherapy and Oncology., Main Outcome Measures: Self-reported practice, knowledge, barriers, need for training and responsibility attitudes in regard to demographic characteristics., Results: Of the surveyed sample, 54.6% of the radiation oncologists completed the instrument (n = 119). Frequency of discussing sexual function was fluctuating, depending on the type of tumor. The majority of the responding radiation oncologists (75%) agreed that discussing sexual function is their responsibility, about one-third (33.6%) pointed at the involved specialist (surgeon, urologist, gynecologist, or oncologist), a fifth also considered the general practitioner responsible (21%). Additional training about discussing sexuality was required according to 44.4%, the majority agreed that sexual counseling should be a regular component of radiation oncology residency (n = 110, 94%). Barriers most mentioned included patient is too ill (36.2%), no angle or reason for asking (32.4%), advanced age of the patient (27%) and culture/religion (26.1%). For prostate cancer patients, phosphodiesterase 5 inhibitor information was supplied regularly (49.2%) and often (40.7%)., Conclusions: Radiation oncologists generally perform sexual counseling in case of pelvic radiation therapy, but not consistently in case of gastrointestinal, breast, and other cancers. The majority of radiation oncologists considered counseling on sexual functioning as a part of their job, some also pointed at the referring specialist or general practitioner. The findings suggest that awareness about sexual dysfunction is present among radiation oncologists, but responsibility for active counseling is uncertain. Results emphasize the need for providing educational and practical training, as well as a list for specialized referral., (© 2015 International Society for Sexual Medicine.)
- Published
- 2015
- Full Text
- View/download PDF
39. Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-rays.
- Author
-
van Nimwegen FA, Cutter DJ, Schaapveld M, Rutten A, Kooijman K, Krol AD, Janus CP, Darby SC, van Leeuwen FE, and Aleman BM
- Subjects
- Adolescent, Adult, Case-Control Studies, Female, Heart diagnostic imaging, Hodgkin Disease diagnostic imaging, Hodgkin Disease mortality, Humans, Lymph Nodes diagnostic imaging, Lymph Nodes radiation effects, Male, Middle Aged, Observer Variation, Organs at Risk diagnostic imaging, Radiation Dosage, Radiography, Reproducibility of Results, Spleen diagnostic imaging, Spleen radiation effects, Survivors, Young Adult, Heart radiation effects, Hodgkin Disease radiotherapy, Organs at Risk radiation effects
- Abstract
Purpose: To describe a new method to estimate the mean heart dose for Hodgkin lymphoma patients treated several decades ago, using delineation of the heart on radiation therapy simulation X-rays. Mean heart dose is an important predictor for late cardiovascular complications after Hodgkin lymphoma (HL) treatment. For patients treated before the era of computed tomography (CT)-based radiotherapy planning, retrospective estimation of radiation dose to the heart can be labor intensive., Methods and Materials: Patients for whom cardiac radiation doses had previously been estimated by reconstruction of individual treatments on representative CT data sets were selected at random from a case-control study of 5-year Hodgkin lymphoma survivors (n=289). For 42 patients, cardiac contours were outlined on each patient's simulation X-ray by 4 different raters, and the mean heart dose was estimated as the percentage of the cardiac contour within the radiation field multiplied by the prescribed mediastinal dose and divided by a correction factor obtained by comparison with individual CT-based dosimetry., Results: According to the simulation X-ray method, the medians of the mean heart doses obtained from the cardiac contours outlined by the 4 raters were 30 Gy, 30 Gy, 31 Gy, and 31 Gy, respectively, following prescribed mediastinal doses of 25-42 Gy. The absolute-agreement intraclass correlation coefficient was 0.93 (95% confidence interval 0.85-0.97), indicating excellent agreement. Mean heart dose was 30.4 Gy with the simulation X-ray method, versus 30.2 Gy with the representative CT-based dosimetry, and the between-method absolute-agreement intraclass correlation coefficient was 0.87 (95% confidence interval 0.80-0.95), indicating good agreement between the two methods., Conclusion: Estimating mean heart dose from radiation therapy simulation X-rays is reproducible and fast, takes individual anatomy into account, and yields results comparable to the labor-intensive representative CT-based method. This simpler method may produce a meaningful measure of mean heart dose for use in studies of late cardiac complications., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
40. Risk of valvular heart disease after treatment for Hodgkin lymphoma.
- Author
-
Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, and Aleman BM
- Subjects
- Adolescent, Adult, Aged, Aortic Valve radiation effects, Case-Control Studies, Dose-Response Relationship, Radiation, Female, Hodgkin Disease surgery, Humans, Male, Middle Aged, Mitral Valve radiation effects, Odds Ratio, Radiotherapy Dosage, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Young Adult, Heart Valve Diseases etiology, Hodgkin Disease radiotherapy, Radiation Injuries etiology, Splenectomy adverse effects
- Abstract
Background: Hodgkin lymphoma (HL) survivors are at increased risk of developing valvular heart disease (VHD). We evaluated the determinants of the risk and the radiation dose-response., Methods: A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical tests were two-sided., Results: Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with radiation dose. For doses to the affected valve(s) of less than or equal to 30, 31-35, 36-40, and more than 40 Gy, VHD rates increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively (P trend < .001). Approximate 30-year cumulative risks were 3.0%, 6.4%, 9.3%, and 12.4% for the same dose categories. VHD rate increased with splenectomy by a factor of 2.3 (P = .02)., Conclusions: Radiation dose to the heart valves can increase the risk of clinically significant VHD, especially at doses above 30 Gy. However, for patients with mediastinal involvement treated today with 20 or 30 Gy, the 30-year risk will be increased by only about 1.4%. These findings may be useful for patients and doctors both before treatment and during follow-up., (© The Author 2015. Published by Oxford University Press.)
- Published
- 2015
- Full Text
- View/download PDF
41. Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma.
- Author
-
Daniëls LA, Krol AD, Schaapveld M, Putter H, Jansen PM, Marijt EW, van Leeuwen FE, and Creutzberg CL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cohort Studies, Female, Humans, Male, Middle Aged, Radiotherapy adverse effects, Retrospective Studies, Hodgkin Disease radiotherapy, Neoplasms, Second Primary etiology, Skin Neoplasms etiology
- Abstract
Purpose: Survivors of Hodgkin's lymphoma (HL) are at risk of secondary tumors. We investigated the risk of secondary skin cancers after radiotherapy compared to treatment without radiation and to an age-matched population., Material and Methods: We conducted a retrospective cohort study of 889 HL patients treated between 1965 and 2005. Data on secondary skin cancers and treatment fields were retrieved. Incidence rates were compared to observed rates in the Dutch population., Results: 318 skin cancers were diagnosed in 86 patients, showing significantly higher risks of skin cancers, the majority being BCC. The standardized incidence ratio (SIR) of BCC in HL survivors was significantly increased (SIR 5.2, 95% CI 4.0-6.6), especially in those aged <35 years at diagnosis (SIR 8.0, 95% CI 5.8-10.7). SIR increased with longer follow-up to 15.9 (95% CI 9.1-25.9) after 35 years, with 626 excess cases per 10,000 patients per year. Most (57%) skin cancers developed within the radiation fields, with significantly increased risk in patients treated with radiotherapy compared to chemotherapy alone (p=0·047, HR 2·75, 95% CI 1·01-7.45)., Conclusion: Radiotherapy for HL is associated with a strongly increased long-term risk of secondary skin cancers, both compared to the general population and to treatment with chemotherapy alone., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
42. Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable.
- Author
-
Moojen WA, Vleggeert-Lankamp CL, Krol AD, and Dijkstra SP
- Subjects
- Adult, Aged, Chordoma mortality, Chordoma pathology, Coccyx pathology, Cross-Sectional Studies, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Netherlands epidemiology, Retrospective Studies, Sacrum pathology, Spinal Neoplasms mortality, Spinal Neoplasms pathology, Spine pathology, Survival Rate, Chordoma therapy, Coccyx surgery, Radiotherapy, Adjuvant methods, Sacrum surgery, Spinal Neoplasms therapy, Spine surgery
- Abstract
Study Design: A cross-sectional study., Objective: The purpose of this report is to define the role of postoperative radiotherapy in the prevention of local recurrence (LR)., Summary of Background Data: Sacrococcygeal chordoma is a slow growing, malignant tumor with a clinical poor outcome due to a high LR rate. Several studies emphasize that margin-free tumor resection is the most important predictor of LR. However, even after extralesional resection a high LR up to 80% remains., Methods: A retrospective series of 15 patients who underwent surgical treatment for sacrococcygeal chordoma in one center between 1981 and 2003 was reviewed. Overall survival and continuous disease-free survival rates were compared between patients with intralesional resection with standard radiotherapy and patients with extralesional resection and no standard radiotherapy., Results: The median age at surgery was 53 years. The mean follow-up was 7 years or until death. Mean duration of preoperative complaints was 3 years. In 10 patients, an en bloc resection was (histologic resection margins were free) performed and in 5 patients, an intralesional resection was achieved. All but one patients with intralesional resection received radiotherapy (>50 Gy) and patients with extralesional resection only received radiotherapy in case of LR (6 of 10 patients). After extralesional resection (no initial radiotherapy), all 10 patients had LR of the tumor with a mean time to recurrence of 2 years. Six of these ten patients received radiotherapy after LR and had mean survival duration of 7 years. Only one (of five patients) in the group with intralesional resection and postoperative radiotherapy had LR after 11 years. The time to recurrence was significantly longer and we found a trend toward a longer overall survival in the group that received immediate radiotherapy after surgery., Conclusion: The results support the strategy to add radiotherapy as standard adjuvant therapy to sacrococcygeal chordoma tumor resection.
- Published
- 2011
- Full Text
- View/download PDF
43. Re: Late effects from radiation therapy: the hits just keep on coming.
- Author
-
Aleman BM, de Bruin ML, Dorresteijn LD, Krol AD, van 't Veer MB, Boogerd W, and van Leeuwen FE
- Subjects
- Dose-Response Relationship, Radiation, Hodgkin Disease drug therapy, Humans, Ischemic Attack, Transient epidemiology, Radiation Injuries epidemiology, Radiation Injuries etiology, Radiation Injuries prevention & control, Radiotherapy adverse effects, Radiotherapy Dosage, Risk Assessment, Risk Factors, Stroke epidemiology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Heart radiation effects, Hodgkin Disease radiotherapy, Ischemic Attack, Transient etiology, Radiation Injuries complications, Stroke etiology
- Published
- 2010
- Full Text
- View/download PDF
44. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
- Author
-
Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, and Henry-Amar M
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bleomycin administration & dosage, Combined Modality Therapy, Doxorubicin administration & dosage, Epirubicin administration & dosage, Female, Follow-Up Studies, Hodgkin Disease pathology, Humans, Male, Mechlorethamine administration & dosage, Middle Aged, Neoplasm Staging, Neoplasms, Second Primary chemically induced, Prednisone administration & dosage, Procarbazine administration & dosage, Survival Analysis, Treatment Outcome, Vinblastine administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy
- Abstract
Purpose: In early-stage Hodgkin's lymphoma (HL), subtotal nodal irradiation (STNI) and combined chemotherapy/radiotherapy produce high disease control rates but also considerable late toxicity. The aim of this study was to reduce this toxicity using a combination of low-intensity chemotherapy and involved-field radiotherapy (IF-RT) without jeopardizing disease control., Patients and Methods: Patients with stage I or II HL were stratified into two groups, favorable and unfavorable, based on the following four prognostic factors: age, symptoms, number of involved areas, and mediastinal-thoracic ratio. The experimental therapy consisted of six cycles of epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by IF-RT. It was randomly compared, in favorable patients, to STNI and, in unfavorable patients, to six cycles of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV hybrid) and IF-RT., Results: Median follow-up time of the 722 patients included was 9 years. In 333 favorable patients, the 10-year event-free survival rates (EFS) were 88% in the EBVP arm and 78% in the STNI arm (P = .0113), with similar 10-year overall survival (OS) rates (92% v 92%, respectively; P = .79). In 389 unfavorable patients, the 10-year EFS rate was 88% in the MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS rates of 87% and 79%, respectively (P = .0175)., Conclusion: A treatment strategy for early-stage HL based on prognostic factors leads to high OS rates in both favorable and unfavorable patients. In favorable patients, the combination of EBVP and IF-RT can replace STNI as standard treatment. In unfavorable patients, EBVP is significantly less efficient than MOPP/ABV.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.